The historical rank and industry rank for BRAIN Biotech AG's Pretax Margin % or its related term are showing as below:
HAM:BNN'
s Pretax Margin % Range Over the Past 10 Years
Min: -63.3 Med: -25.03 Max: -11.14
Current: -23.53
HAM:BNN's Pretax Margin % is ranked worse than 92.15% of 1579
companies
in the Chemicals industry
Industry Median: 5.33
vs HAM:BNN: -23.53
BRAIN Biotech AG (HAM:BNN) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BRAIN Biotech AG Pretax Margin % Related Terms
BRAIN Biotech AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BNN vs LIN, SHW, ECL: Pretax Margin % Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Pretax Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Pretax Margin % of -31.68% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BRAIN Biotech AG and its competitors. According to the industry distribution chart, BRAIN Biotech AG ranks #1455 out of 1579 companies in the Chemicals industry, placing it in the top 92.1%.
Is BRAIN Biotech AG's Pretax Margin % too high?
BRAIN Biotech AG's current Pretax Margin % is -31.68%. Based on the distribution chart, BRAIN Biotech AG ranks #1455 out of 1579 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Pretax Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #1455 out of 1579 companies for Pretax Margin %. This places BRAIN Biotech AG in the lower half of its industry. The industry median Pretax Margin % is 5.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Chemicals company?
The median Pretax Margin % among Chemicals companies is 5.33, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Pretax Margin % is 5.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Pretax Margin % is -31.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.56, compared to a current price of €2.72 — trading 6.3% above its estimated fair value. The current Pretax Margin % is -31.68%. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Pretax Margin % is -31.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.72 is trading 6.3% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
Pretax Margin %: -31.68%
GF Value™: €2.56 vs. price of €2.72 (6.3% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
